Trial watch: Dendritic cell-based anticancer therapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Oncoimmunology

• Publication date

  2014-10-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/21624011.2014.963424PMID 25941593PMCID PMC4292311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tolerogenic dendritic cells

  2016cited by this paper
• Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases

  2015cited by this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cited by this paper
• Trial Watch

  2014cited by this paper
• Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

  2014cited by this paper
• Lymph node stromal cells acquire peptide–MHCII complexes from dendritic cells and induce antigen-specific CD4+ T cell tolerance

  2014cited by this paper
• Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

  2014cited by this paper
• Trial Watch

  2014cited by this paper
• Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

  2014cited by this paper
• Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer—A Phase I-II Study

  2014cited by this paper
• Recent advances and new opportunities for targeting human dendritic cells in situ

  2014cited by this paper
• Two is better than one

  2014cited by this paper
• GM-CSF facilitates the development of inflammation-associated colorectal carcinoma

  2014cited by this paper
• A dual role for autophagy in a murine model of lung cancer

  2014cited by this paper
• Trial Watch: Radioimmunotherapy for oncological indications

  2014cited by this paper
• A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

  2014cited by this paper
• Trial Watch

  2014cited by this paper
• Induction and Activation of Human Th17 by Targeting Antigens to Dendritic Cells via Dectin-1

  2014cited by this paper
• A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma

  2014cited by this paper
• Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma

  2014cited by this paper
• Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

  2014cited by this paper
• Trial watch

  2014cited by this paper
• Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care.

  2014cited by this paper
• Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study

  2014cited by this paper
• Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

  2014cited by this paper
• Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial

  2014cited by this paper
• Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking

  2014cited by this paper
• Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells

  2014cited by this paper
• Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response

  2014cited by this paper
• Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer

  2014cited by this paper
• Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

  2014cited by this paper
• Proof of Principle

  2014cited by this paper
• Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

  2014cited by this paper
• A Single Subset of Dendritic Cells Controls the Cytokine Bias of Natural Killer T Cell Responses to Diverse Glycolipid Antigens

  2014cited by this paper
• Development and function of dendritic cell subsets.

  2014cited by this paper
• Trial Watch

  2014cited by this paper
• Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer--a feasibility study.

  2014cited by this paper
• Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients

  2014cited by this paper
• Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer

  2014cited by this paper
• Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients

  2014cited by this paper
• Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis

  2014cited by this paper
• Anti-HER2/Neu passive-aggressive immunotherapy

  2014cited by this paper
• Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

  2014cited by this paper
• Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis.

  2014cited by this paper
• Assembly and localization of Toll-like receptor signalling complexes

  2014cited by this paper
• Sequential infusion of donor‐derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation

  2014cited by this paper
• Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

  2014cited by this paper
• Oral extranodal non Hodgkin's lymphoma: series of forty two cases in Malaysia.

  2014cited by this paper
• Retinoic acid controls the homeostasis of pre-cDC–derived splenic and intestinal dendritic cells

  2013cited by this paper
• Dendritic cell dysregulation during HIV‐1 infection

  2013cited by this paper
• Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis.

  2013cited by this paper
• Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model

  2013cited by this paper
• Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling

  2013cited by this paper
• Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation

  2013cited by this paper
• Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

  2013cited by this paper
• Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS

  2013cited by this paper
• Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

  2013cited by this paper
• Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients

  2013cited by this paper
• TGFβ1 microenvironment determines dendritic cell development

  2013cited by this paper
• Myeloid derived suppressor cells

  2013cited by this paper
• Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer.

  2013cited by this paper
• A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.

  2013cited by this paper
• Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.

  2013cited by this paper
• Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients

  2013cited by this paper
• Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients

  2013cited by this paper
• Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients

  2013cited by this paper
• IL-10 control of dendritic cells in the skin

  2013cited by this paper
• Mechanisms of action of tasquinimod on the tumour microenvironment

  2013cited by this paper
• Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer

  2013cited by this paper
• Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

  2013cited by this paper
• RNA pulsed dendritic cells: an approach for cancer immunotherapy.

  2013cited by this paper
• TLR3 agonists and proinflammatory antitumor activities

  2013cited by this paper
• Dendritic cell vaccination in autoimmune disease

  2013cited by this paper
• Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients

  2013cited by this paper
• p53 status determines the role of autophagy in pancreatic tumour development

  2013cited by this paper
• Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy

  2013cited by this paper
• The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.

  2013influential reference
• Human dendritic cell subsets in vaccination.

  2013cited by this paper
• Human dendritic cells subsets as targets and vectors for therapy

  2013cited by this paper
• Characterization of CD8+ T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)

  2013cited by this paper
• Tasquinimod: a novel drug in advanced prostate cancer.

  2013cited by this paper
• Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments

  2013cited by this paper
• Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis

  2013cited by this paper
• Cytokine-induced killer cells promote antitumor immunity

  2013cited by this paper
• Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients

  2013cited by this paper
• Targeting survivin in cancer.

  2013cited by this paper
• [The effect of immunotherapy and hyperthermia on patients with advanced or recurrent breast cancer].

  2013cited by this paper
• Designing tomorrow's vaccines.

  2013cited by this paper
• Targeting Antigens to Dendritic Cell Receptors for Vaccine Development

  2013cited by this paper
• Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

  2013cited by this paper
• Roles of TLR7 in Activation of NF-κB Signaling of Keratinocytes by Imiquimod

  2013cited by this paper
• Trial Watch

  2013cited by this paper
• Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

  2013cited by this paper
• Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells.

  2013cited by this paper
• Trial Watch

  2013cited by this paper
• Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage.

  2013cited by this paper
• Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer

  2013cited by this paper
• Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study

  2013cited by this paper
• IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

  2013cited by this paper
• Fusions between dendritic cells and whole tumor cells as anticancer vaccines

  2013cited by this paper

• Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.

  2024cites this paper
• Current status and future of cancer vaccines: A bibliographic study

  2024cites this paper
• A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.

  2024cites this paper
• Advances in dendritic cell vaccination therapy of cancer.

  2023cites this paper
• Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy

  2023cites this paper
• Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing

  2023cites this paper
• Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies

  2022cites this paper
• Directly injected lentiviral vector–based T cell vaccine protects mice against acute and chronic viral infection

  2022cites this paper
• Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine

  2020cites this paper
• Necroptotic‐susceptible dendritic cells exhibit enhanced antitumor activities in mice

  2020cites this paper
• Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response

  2020cites this paper
• Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

  2019cites this paper
• Developments in anticancer vaccination: budding new adjuvants

  2019cites this paper
• Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD‐L1)‐mediated immunosuppression

  2019cites this paper
• The immunostimulatory effects and pro‐apoptotic activity of rhCNB against Lewis lung cancer is mediated by Toll‐like receptor 4

  2019cites this paper
• Improved dendritic cell therapy for cancer by enhancing in vivo lymph node migration using a novel chemokine-based sorting method

  2019cites this paper
• Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results

  2019cites this paper
• Imiquimod enhances the potency of an exogenous BM‐DC based vaccine against mouse melanoma

  2018cites this paper
• 3-Day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin E2 are a promising alternative for cancer immunotherapy

  2018cites this paper
• Combination Immunotherapy: Taking Cancer Vaccines to the Next Level

  2018cites this paper
• Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy

  2018cites this paper
• Immunogenic effects of chemotherapy-induced tumor cell death

  2018cites this paper
• Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus: An in vivo study.

  2018cites this paper
• Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy.

  2018cites this paper
• Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

  2018cites this paper
• Cancer Vaccines in Pediatrics

  2018cites this paper
• Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy.

  2018cites this paper
• Trial watch: Dendritic cell-based anticancer immunotherapy

  2017cites this paper
• Modifying Dendritic Cell Activation with Plasmonic Nano Vectors

  2017cites this paper
• Targeting Autophagy in ALK-Associated Cancers

  2017cites this paper
• eview he cancer-immunity cycle as rational design for synthetic cancer rugs : Novel DC vaccines and CAR T-cells

  2017cites this paper
• Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models

  2017cites this paper
• Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

  2017cites this paper
• Inflammatory microenvironment in the initiation and progression of bladder cancer

  2017cites this paper
• Dual Functional Capability of Dendritic Cells – Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy

  2017cites this paper
• Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.

  2017cites this paper
• Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists

  2017cites this paper
• STAT3 and NF-κB are Simultaneously Suppressed in Dendritic Cells in Lung Cancer

  2017cites this paper
• Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

  2017cites this paper
• Candidate immune biomarkers for radioimmunotherapy.

  2017cites this paper
• Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination

  2017cites this paper
• Trial watch: DNA-based vaccines for oncological indications

  2017cites this paper
• The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.

  2017cites this paper
• Exploiting tumor‐associated dendritic cell heterogeneity for novel cancer therapies

  2017cites this paper
• Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials.

  2017cites this paper
• Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy

  2017cites this paper
• Cancer-Host Interactions Influencing Disease Progression and Therapy

  2017cites this paper
• Trial Watch—Immunostimulation with cytokines in cancer therapy

  2016cites this paper
• Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner.

  2016cites this paper
• The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity

  2016cites this paper
• Dendritic-Tumor Fusion Cell-Based Cancer Vaccines

  2016cites this paper
• Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation

  2016cites this paper
• Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives

  2016cites this paper
• A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases

  2016cites this paper
• Functional and Phenotypic Analysis of Two-Day Monocyte-Derived Dendritic Cells Suitable for Immunotherapy Purposes

  2016cites this paper
• Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.

  2016cites this paper
• Activation of Innate Immune Responses by Toll-Like Receptors and Influenza Viruses

  2016cites this paper
• NK cell education and adhesion molecules : implications for immunotherapy

  2016cites this paper
• Evaluation of novel anti-tumoral strategies using peptide or monoclonal antibody immunotherapies

  2016cites this paper
• Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.

  2016cites this paper
• Doubling the blockade for melanoma immunotherapy

  2016cites this paper
• Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles

  2016cites this paper
• Immunogenic cell death in cancer and infectious disease

  2016cites this paper
• Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

  2016cites this paper
• Understanding dendritic cell immunotherapy in ovarian cancer

  2016cites this paper
• Immunological effects of a novel RNA-based adjuvant in liver cancer patients

  2016cites this paper
• The role of myeloid cells in cancer therapies

  2016cites this paper
• Adapting conventional cancer treatment for immunotherapy

  2016cites this paper
• Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

  2015cites this paper
• Quality Verification of Dendritic Cell-Based Cancer Vaccine

  2015cites this paper
• Trial watch: Naked and vectored DNA-based anticancer vaccines

  2015cites this paper
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

  2015cites this paper
• Positive and Negative Impact of Immune Cells on Disease Outcome in Cancer Patients Treated with Chemotherapy Cells Markers Cancer Type

  2015cites this paper
• Novel immune checkpoint blocker approved for the treatment of advanced melanoma

  2014cites this paper
• The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect

  2013cites this paper